Characterization of Neovascular Age-Related Macular Degeneration Patients with Outer Retinal Tubulations
暂无分享,去创建一个
F. Falcão-Reis | Â. Carneiro | E. Brandão | M. Falcão | S. Fonseca | F. Faria-Correia | L. Mendonça | R. Barros-Pereira | L. Queirós-Mendanha
[1] C. Curcio,et al. ANATOMICAL CORRELATES TO THE BANDS SEEN IN THE OUTER RETINA BY OPTICAL COHERENCE TOMOGRAPHY: Literature Review and Model , 2011, Retina.
[2] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[3] P. Rosenfeld. Bevacizumab versus ranibizumab for AMD. , 2011, The New England journal of medicine.
[4] Masayuki Hata,et al. The significance of external limiting membrane status for visual acuity in age-related macular degeneration. , 2010, American journal of ophthalmology.
[5] E. Chew,et al. Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices , 2009, Eye.
[6] K Bailey Freund,et al. Outer retinal tubulation: a novel optical coherence tomography finding. , 2009, Archives of ophthalmology.
[7] R. Forte,et al. Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume , 2009, Eye.
[8] A. Tsujikawa,et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. , 2009, American journal of ophthalmology.
[9] P. Mitchell,et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials , 2009, British Journal of Ophthalmology.
[10] Sumit Sharma,et al. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. , 2009, Ophthalmology.
[11] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[12] William J Feuer,et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[13] S. Resnikoff,et al. Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.
[14] H. Grossniklaus,et al. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. , 1998, American journal of ophthalmology.
[15] P. Liao,et al. Stereoscopic Atlas of Macular Diseases. Diagnosis and Treatment , 1987, The Yale Journal of Biology and Medicine.